Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-Current Deffered Revenue: 2016-2024

Historic Non-Current Deffered Revenue for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $12.1 million.

  • Tg Therapeutics' Non-Current Deffered Revenue fell 48.36% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year decrease of 48.36%. This contributed to the annual value of $12.1 million for FY2024, which is 100.88% up from last year.
  • Latest data reveals that Tg Therapeutics reported Non-Current Deffered Revenue of $12.1 million as of FY2024, which was up 100.88% from $6.0 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Non-Current Deffered Revenue ranged from a high of $12.1 million in FY2024 and a low of $305,000 during FY2022.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $6.0 million (2023), whereas its average is $6.1 million.
  • As far as peak fluctuations go, Tg Therapeutics' Non-Current Deffered Revenue plummeted by 33.26% in 2022, and later surged by 1,872.46% in 2023.
  • Tg Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $610,000 in 2020, then dropped by 25.08% to $457,000 in 2021, then slumped by 33.26% to $305,000 in 2022, then skyrocketed by 1,872.46% to $6.0 million in 2023, then soared by 100.88% to $12.1 million in 2024.